Concurrent AXL Inhibition Enhances RAS and ERK Inhibitor Efficacy in KRAS-mutant Pancreatic and Lung Cancer

Yan-Pang Ching Shruthi Narayanan Jeffrey A. Klomp Tamara Isermann Sina Loewe Wen-Hsuan Chang Andrew M. Waters Sheila R. Nicewarner Peña E. Baldelli A. C. Edwards Teresa Börding Run-Wei Yang Craig M. Goodwin Prson Gautam M. Ponz-Sarvisé David Horst Kyle J. Seamon Yong-Xian Zhuang Linh Tran Jing-Jing Jiang Mallika Singh K. Wennerberg E. Petricoin Kirsten L. Bryant Clint A. Stalnecker H. Earp Adrienne D. Cox C. Sers S. Vicent C. Der Bjoern Papke

Aug 2026 · bioRxiv · 0 citations

Biology

TL;DR

Combined treatment with the AXL inhibitor bemcentinib together with the RAS(ON) multi-selective tri-complex inhibitor RMC-7977 (RASi) or the ERK-selective inhibitor SCH772984 (ERKi) significantly enhanced growth suppression in human KRAS-mutant pancreatic and lung cancer models.

DOI Semantic Scholar

View source

Similar papers

Open access Aug 2026

Targeting AXL Overcomes Adaptive Resistance to KRAS Inhibition in KRAS-Driven Cancer

By integrating adaptive response to KRAS inhibition with anti-tumor immunity, AXL represents a mechanistically actionable vulnerability whose inhibition deepens and prolongs responses to both allele-specific and pan-KRAS-targeted therapies.

F. Thege, A. Kramer, Norbert Kreisz et al. · bioRxiv · 0 citations

Open access Sep 2026

Targeting Compensatory AKT Activation Overcomes Resistance to AXL Inhibition in Acute Lymphoblastic Leukemia.

The GAS6/AXL pathway plays a crucial role in promoting tumor survival and therapy resistance in various cancers. However, its significance in acute lymphoblastic leukemia (ALL) and the potential for its therapeutic targeting remain incompletely characterized. We integrated transcriptomic analysis of the public dataset...

Hai-Hong Gao, Yi Zhan, Miao-Ying Bao et al. · Molecular Cancer Therapeutic... · 0 citations

Aug 2026

XPO1 inhibition enhances the efficacy and durability of RAS-targeted therapy in preclinical models of KRASG12D mutant pancreatic ductal adenocarcinoma.

KRASG12D-selective and pan-RAS inhibitors have shown promise in pancreatic ductal adenocarcinoma (PDAC), yet adaptive resistance is anticipated to limit durability of response. Exportin 1 (XPO1), a nuclear export protein frequently overexpressed in PDAC, represents a potential vulnerability in KRAS-mutant cancers. We e...

H. Y. Khan, M. Al-Hallak, A. Aboukameel et al. · Cancer Letters · 0 citations

Sep 2026

Abstract B054: Combined RAS Inhibition and Immune Checkpoint Blockade Overcome NF-κB-Mediated Immune Evasion in Chemoresistant Pancreatic Cancer

Pancreatic ductal adenocarcinoma (PDAC) remains one of the most lethal malignancies. Surgery is the only potentially curative treatment, yet approximately 85% of patients present with unresectable disease. For these patients, chemotherapy remains the standard treatment, though nearly all develop resistance and diseas...

K. Gulay, A. Martsinkovskiy, A. Lowy et al. · Cancer Research · 0 citations

Sep 2026

Abstract B068: FYN and other Src family kinases antagonize response to RAS inhibition in pancreatic ductal adenocarcinoma

Oncogenic KRAS drives pancreatic ductal adenocarcinoma (PDAC), yet resistance to RAS antagonists limit benefits. To define therapeutic response and resistance mechanisms, we deployed two complementary preclinical PDAC models, including a degron-regulated KRASG12D-dependent transplantation model, and a Kras G12V-drive...

Hsiu-Chi Ting, Sun Kim, V. Gaeth et al. · Cancer Research · 0 citations

Sep 2026

Abstract B104: Pharmacological RAS inhibition synergizes with CAR T cells for tumor killing

Despite the success of chimeric antigen receptor (CAR) T cell therapy for liquid cancers, it has provided minimal clinical benefit in solid cancers, including pancreatic ductal adenocarcinoma (PDAC). We have previously shown that pharmacological RAS inhibition favorably remodels the PDAC tumor immune microenviron...

Jayne C. McDevitt, Fei-Yan Mo, Connor J. Hennessey et al. · Cancer Research · 0 citations